Breast Cancer
A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001)
- Details
ClinicalTrials.gov ID:
NCT05629585
Diagnosis Type:
NA
USOR Number:
- Address
1845 W. Orange Grove, Bldg. 2
Tucson, AZ 85704
P: (520) 624-7445
